A systematic review investigating prenatal cannabis and tobacco co-exposure: Impacts on neonatal, behavioral, cognitive and physiological outcomes
Drug and Alcohol Dependence Reports · 2025-12 · 17 · 100376
DOI: 10.1016/j.dadr.2025.100376 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug and Alcohol Dependence Reports, 2025-12. Verfasst von Mathilde Argote und 3 weiteren Autor:innen. Beteiligte Einrichtung: McGill University, Montreal, Canada. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de recherche du Québec Santé, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Background
Despite the high and increasing rates of cannabis and nicotine/tobacco product (NTP) use during pregnancy, the impact of their combined use on health outcomes in offspring remains poorly understood. Given the growing body of research on prenatal cannabis and NTP co-exposure and its effects on neonatal, behavioral, cognitive, and physiological outcomes in offspring, we conducted a systematic review to synthesize the existing literature and evaluate whether prenatal co-exposure results in additive and/or synergistic adverse effects compared to prenatal cannabis-only exposure and prenatal NTP-only exposure.
Methods
We searched Medline, Embase, and PsycINFO databases via OVID for human and animal studies examining the association between prenatal co-exposure and single-substance exposure on neonatal, behavioral, cognitive, and physiological outcomes in offspring.
Results
Of 3217 records identified, 46 articles were included in the review (human, n = 43; preclinical n = 3). For select neonatal outcomes, co-exposed infants exhibited a higher risk of compromised physical development and birth defects relative to infants with single-substance exposure. Behavioral outcomes, particularly emotion regulation/reactivity, and physiological outcomes demonstrated a similar pattern. In contrast, other neonatal outcomes (e.g., preterm birth and respiratory distress), and cognition were similar between the prenatal co-exposure and single-substance exposure groups.
Conclusions
This review suggests additive and/or synergistic adverse consequences associated with co-exposure on several outcomes in offspring relative to single substance exposure. These findings highlight the urgent need for prevention and treatment strategies addressing cannabis and NTP use in pregnant women. We discuss the limitations of the included studies and highlight key areas for future research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- McGill University, Montreal, Canada.
- The Douglas Mental Health University Institute, Verdun, Canada.
- Institute of Medical Sciences, University of Toronto and Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, ON, Canada.
- Department of Psychiatry, McGill University, Montreal, Canada.
Förderung
- Fonds de recherche du Québec Santé
- Canadian Institutes of Health Research
Zitieren
APA
Argote, M., Hilson, L., Sorkhou, M., & Rabin, R. A. (2025). A systematic review investigating prenatal cannabis and tobacco co-exposure: Impacts on neonatal, behavioral, cognitive and physiological outcomes. Drug and Alcohol Dependence Reports, 17, 100376. https://doi.org/10.1016/j.dadr.2025.100376
Vancouver
Argote M, Hilson L, Sorkhou M, Rabin RA. A systematic review investigating prenatal cannabis and tobacco co-exposure: Impacts on neonatal, behavioral, cognitive and physiological outcomes. Drug and Alcohol Dependence Reports. 2025;17:100376. doi:10.1016/j.dadr.2025.100376
BibTeX
@article{Argote2025,
author = {Argote, Mathilde and Hilson, Leah and Sorkhou, Maryam and Rabin, Rachel A},
title = {A systematic review investigating prenatal cannabis and tobacco co-exposure: Impacts on neonatal, behavioral, cognitive and physiological outcomes},
journal = {Drug and Alcohol Dependence Reports},
year = {2025},
volume = {17},
pages = {100376},
doi = {10.1016/j.dadr.2025.100376}
}
EUVIMED